Allogene Therapeutics Inc ALLO.OQ ALLO.O is expected to show a fall in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
The South San Francisco California-based company is expected to report a 91.7% decrease in revenue to $1.82 thousand from $22 thousand a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Allogene Therapeutics Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Allogene Therapeutics Inc is $9.00, above its last closing price of $1.18.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.38 | -0.33 | -0.28 | Beat | 16 |
Sep. 30 2024 | -0.33 | -0.33 | -0.32 | Beat | 2.8 |
Jun. 30 2024 | -0.34 | -0.35 | -0.35 | Met | -0.8 |
Mar. 31 2024 | -0.40 | -0.41 | -0.38 | Beat | 7.2 |
Dec. 31 2023 | -0.41 | -0.45 | -0.43 | Beat | 4.3 |
Sep. 30 2023 | -0.51 | -0.52 | -0.37 | Beat | 28.8 |
Jun. 30 2023 | -0.60 | -0.59 | -0.53 | Beat | 10 |
Mar. 31 2023 | -0.63 | -0.62 | -0.68 | Missed | -10.2 |
This summary was machine generated May 9 at 21:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。